Leerink analyst Joseph Schwartz notes BioMarin (BMRN) believes INZ-701 could be a $400M-$600M opportunity at peak, making it ...

Fintel reports that on May 14, 2025, Leerink Partners downgraded their outlook for iTeos Therapeutics (NasdaqGM:ITOS) from ...

Fintel reports that on May 13, 2025, Leerink Partners downgraded their outlook for Halozyme Therapeutics (NasdaqGS:HALO) from ...

Johnson & Johnson (NYSE:JNJ) stock and Halozyme (HALO) stock were downgraded at Leerink Partners on earlier than expected price controls for products. Read more here.

Fintel reports that on May 13, 2025, Leerink Partners downgraded their outlook for Halozyme Therapeutics (BIT:1HALO) from Market Perform to Underperform. There are 1,095 funds or institutions ...

Fintel reports that on May 13, 2025, Leerink Partners downgraded their outlook for Halozyme Therapeutics (LSE:0J2O) from Market Perform to Underperform. As of May 7, 2025, the average one-year ...

When available, copies of the preliminary prospectus supplement and the accompanying prospectus relating to this offering may also be obtained by contacting: Leerink Partners LLC, Syndicate ...

Leerink initiated coverage of Spyre Therapeutics (SYRE) with an Outperform rating and $45 price target Discover outperforming stocks and invest smarter with Top Smart Score Stocks. Filter ...

In addition to eliciting greater weight loss than Novo Nordisk’s Wegovy, Eli Lilly’s Zepbound does not come at the expense of ...

Live Updates Live Coverage Updates appear automatically as they are published. Moving On Up 10:09 am After opening barely ...

According to CEO Daniel Vitt, clinical and disability-related outcomes are more relevant than brain volume change for drug ...

Leerink Partners analyst David Risinger maintained a Sell rating on Moderna (MRNA – Research Report) yesterday and set a price target of $23.00. Discover outperforming stocks and invest smarter ...